Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Irritable bowel syndrome cost-effectiveness of therapy

Introduction

Cost-effectiveness of therapy

Cost-effectiveness of therapy

  • The aggregate cost of IBS in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.[1]
  • A 49% annual increase in medical costs is associated with a diagnosis of IBS.[2][3]
  • IBS patients have average annual direct costs of $5,049 and $406 in out-of-pocket expenses.[4]
  • IBS patients have a reported 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.[5]
  • IBS patients have high costs for physician visits, outpatients visits, and prescription drugs.
  • In 2007, IBS was associated with an increase of $962 in Medicaid costs in California, and $2191 in North Carolina.
  • Cost of IBS is comparable to asthma patients.[6]
Research spending on IBS

Research spending on IBS

Further information: NIH funding of IBS Research
References

References

  1. ↑ Hulisz D. (2004). “The burden of illness of irritable bowel syndrome: current challenges and hope for the future”. J Manag Care Pharm. 10 (4): 299–309. PMID 15298528.
  2. ↑ Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. (2001). “Costs of care for irritable bowel syndrome patients in a health maintenance organization”. Am J Gastroenterol. 96 (11): 3122–9. PMID 11721759.
  3. ↑ Leong SA, Barghout V, Birnbaum HG; et al. (2003). “The economic consequences of irritable bowel syndrome: a US employer perspective”. Arch. Intern. Med. 163 (8): 929–35. doi:10.1001/archinte.163.8.929. PMID 12719202.
  4. ↑ “Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain”. Aliment Pharmacol Ther. 26 (2): 237–48. 2007. PMID 17593069. Text ” author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. ” ignored (help)
  5. ↑ Paré P, Gray J, Lam S; et al. (2006). “Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study”. Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
  6. ↑ Martin B, Ganguly R, Pannicker S, Feride F;Barghout V (2003). “Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome”. Curr Med Res Opin. 19 (8): 771–780. PMID 12719202.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]